Publications by authors named "Karina Raikhelson"
Article Synopsis
- The ENHANCE study assessed the efficacy and safety of seladelpar, a PPAR-δ agonist, in patients with primary biliary cholangitis who didn't respond well to or couldn't tolerate traditional treatment with UDCA.
- Participants were divided into three groups receiving either seladelpar (5 mg or 10 mg) or a placebo, with the primary goal of measuring liver function improvements after 12 months.
- Results showed that patients receiving 10 mg of seladelpar had significant liver function improvements and reduced itching compared to placebo, and the treatment was deemed safe with no serious side effects reported.
